Seeing Is Believing
Currently out of the existing stock ratings of Kelsey Goodwin, 34 are a BUY (94.44%), 2 are a HOLD (5.56%).
Analyst Kelsey Goodwin, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 53.21% that have a potential upside of 29.44% achieved within 80 days.
Kelsey Goodwin’s has documented 67 price targets and ratings displayed on 13 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CGON, CG Oncology, Common stock at 07-Aug-2026.
Analyst best performing recommendations are on NUVL (NUVALENT).
The best stock recommendation documented was for NUVL (NUVALENT) at 9/16/2024. The price target of $105 was fulfilled within 1 day with a profit of $7.17 (6.39%) receiving and performance score of 63.92.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 31-Oct-2022
$115
$-0.07 (-0.06%)
6 months 20 days ago
(26-Feb-2026)
2/2 (100%)
$1.12 (0.98%)
110
Buy Since 24-Feb-2026
$115
$-0.07 (-0.06%)
$85
6 months 22 days ago
(24-Feb-2026)
2/2 (100%)
$1.25 (1.10%)
90
Buy Since 20-Jun-2023
$120
$4.93 (4.28%)
$136
6 months 22 days ago
(24-Feb-2026)
4/6 (66.67%)
$6.25 (5.49%)
192
Buy Since 01-Mar-2022
$115
$-0.07 (-0.06%)
$39
6 months 22 days ago
(24-Feb-2026)
9/9 (100%)
$1.25 (1.10%)
279
Buy Since 17-Jun-2025
$115
$-0.07 (-0.06%)
$110
6 months 22 days ago
(24-Feb-2026)
2/2 (100%)
$1.25 (1.10%)
151
Which stock is Kelsey Goodwin most bullish on?
Which stock is Kelsey Goodwin most reserved on?
What Year was the first public recommendation made by Kelsey Goodwin?